RecruitingNCT05868902

A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients With Suspected Coronary Ischemia.

Sponsor

Genetesis Inc.

Enrollment

300 participants

Start Date

Aug 28, 2023

Study Type

OBSERVATIONAL

Conditions

Coronary; Ischemic

Summary

A multicenter observational data development registry collecting diagnostic measures via standard of care (SOC) cardiac PET in order gain a better understanding of how CardioFlux MCG may be used in the detection of coronary ischemia.

Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called CardioFlux Magnetocardiography for people with coronary; ischemic. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 40 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECardioFlux Magnetocardiography

The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)

Locations(2)

Cleveland Clinic

Cleveland, Ohio, United States

Kettering Health

Kettering, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05868902

Related Trials

iCorMicA - Stratified Medicine in Angina

NCT0467444939 locations

Clinical Utility and Outcome Prediction of Cardiovascular Computed Tomography (PREDICT-CT)

NCT048273161 location